- Home
- MUA vs FDMT Comparison
MUA vs FDMT Comparison
Compare MUA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | FDMT |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.4M | 455.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MUA | FDMT |
|---|---|---|
| Price | $10.71 | $7.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 92.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $8.61 | $2.24 |
| 52 Week High | $11.43 | $12.34 |
Technical Indicators
Market Signals| Indicator | MUA | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 30.34 |
| Support Level | $10.58 | $7.67 |
| Resistance Level | $10.81 | $11.81 |
| Average True Range (ATR) | 0.16 | 0.73 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 28.05 | 0.88 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.